XML 35 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 12 Months Ended
Mar. 31, 2018
USD ($)
Segment
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Jan. 01, 2018
USD ($)
Jan. 20, 2017
USD ($)
Dec. 31, 2012
USD ($)
Significant Accounting Policies [Line Items]            
Trade receivables, credit period 30 days          
U.S. federal corporate tax rate 21.00%   34.00%      
Number of operating segments | Segment 1          
Accumulated deficit $ (1,296,182,000)   $ (1,271,869,000)      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09            
Significant Accounting Policies [Line Items]            
Accumulated deficit       $ 200,000    
Minimum            
Significant Accounting Policies [Line Items]            
Trade receivables, credit period 30 days          
Maximum            
Significant Accounting Policies [Line Items]            
Trade receivables, credit period 60 days          
Embedded Derivative Financial Instruments | BioPharma Debt            
Significant Accounting Policies [Line Items]            
Maximum repayment of future revenue and receivables           $ 150,000,000
Fair value of embedded derivative liability $ 0   $ 0      
Gain (loss) on change in fair value of derivative liabilities $ 0 $ 0        
Embedded Derivative Financial Instruments | BioPharma Debt | Minimum            
Significant Accounting Policies [Line Items]            
Derivative liability fair value assumptions, term 2 years   2 years 3 months 18 days      
Derivative liability fair value assumption, coupon rate 5.80%   5.80%      
Derivative liability fair value assumptions, market yields 7.80%   10.20%      
Embedded Derivative Financial Instruments | BioPharma Debt | Maximum            
Significant Accounting Policies [Line Items]            
Derivative liability fair value assumptions, term 4 years   4 years 3 months 18 days      
Derivative liability fair value assumption, coupon rate 10.80%   10.80%      
Derivative liability fair value assumptions, market yields 12.70%   18.40%      
Customer A | Gross Product Sales | Customer Concentration Risk            
Significant Accounting Policies [Line Items]            
Concentration risk percentage 26.00% 30.00%        
Customer A | Accounts Receivable | Customer Concentration Risk            
Significant Accounting Policies [Line Items]            
Concentration risk percentage 37.00% 44.00%        
Customer B | Gross Product Sales | Customer Concentration Risk            
Significant Accounting Policies [Line Items]            
Concentration risk percentage 31.00% 27.00%        
Customer B | Accounts Receivable | Customer Concentration Risk            
Significant Accounting Policies [Line Items]            
Concentration risk percentage 30.00% 22.00%        
Customer C | Gross Product Sales | Customer Concentration Risk            
Significant Accounting Policies [Line Items]            
Concentration risk percentage 31.00% 38.00%        
Customer C | Accounts Receivable | Customer Concentration Risk            
Significant Accounting Policies [Line Items]            
Concentration risk percentage 24.00% 31.00%        
2017 Notes            
Significant Accounting Policies [Line Items]            
Aggregate principal amount of notes $ 30,000,000          
Convertible senior notes, discount 1,200,000          
Convertible Debt | 2017 Notes            
Significant Accounting Policies [Line Items]            
Convertible senior notes, discount $ 1,000,000   $ 1,000,000   $ 1,200,000